Quoin Pharmaceuticals Announces Additional Positive 'Whole Body' Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient

Core Insights - Quoin Pharmaceuticals Ltd. has reported highly positive clinical data from its ongoing Investigator Pediatric Netherton Syndrome study, indicating that after 6 weeks of treatment with QRX003, the patient's skin is almost completely healed and there is a significant reduction in the need for other medications [1][2][6] - The treatment has led to the elimination of pruritus, allowing the patient to experience uninterrupted sleep for the first time, which is a critical improvement in quality of life for those suffering from Netherton Syndrome [2][6] - No adverse events have been reported during the 6-week treatment period, and the company has received approval to initiate treatment on a second pediatric patient [2][6] Company Overview - Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products for rare and orphan diseases [5] - The company is committed to addressing unmet medical needs and has a pipeline that includes four products targeting various rare conditions, including Netherton Syndrome [5] Product Information - QRX003 is a topical lotion designed to treat Netherton Syndrome by promoting a normalized skin-shedding process and strengthening the skin barrier [4] - The product utilizes a proprietary delivery technology and contains a broad-spectrum serine protease inhibitor, which mimics the function of the LEKTI protein absent in patients with Netherton Syndrome [4]